Combinatorial Anti-Cancer Effect of Polypurine Reverse Hoogsteen Hairpins against KRAS and MYC Targeting in Prostate and Pancreatic Cancer Cell Lines

被引:0
作者
Valiuska, Simonas [1 ,2 ]
Elder, Kayla K. [3 ]
McKay, Steven J. [3 ]
Ciudad, Carlos J. [1 ,2 ]
Noe, Veronique [1 ,2 ]
Brooks, Tracy A. [3 ]
机构
[1] Univ Barcelona UB, Sch Pharm & Food Sci, Dept Biochem & Physiol, Barcelona 08028, Spain
[2] Univ Barcelona UB, Inst Nanociencia & Nanotecnol IN2UB, Barcelona 08028, Spain
[3] Binghamton Univ, Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Binghamton, NY 13902 USA
关键词
KRAS; MYC; PPRH; G-quadruplex; prostate cancer; pancreatic cancer; C-MYC; K-RAS; SUPPRESSION; DESIGN; DNA;
D O I
10.3390/genes15101332
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Introduction: KRAS and MYC are proto-oncogenes that are strictly regulated in healthy cells that have key roles in several processes such as cell growth, proliferation, differentiation, or apoptosis. These genes are tightly interconnected, and their dysregulation can lead to cancer progression. We previously individually targeted these oncogenes using Polypurine Reverse Hoogsteen (PPRH) hairpins, mostly targeting the complementary strand of G-quadruplex-forming sequences. We validated them in vitro in different cancer cell lines with deregulated KRAS and/or MYC. In this work we focused on our understanding of the cooperative dynamics between these oncogenes, by investigating the combined impact of PPRHs targeting KRAS and MYC in pancreatic and prostate cancer cells. Results: The combinations had a modulatory impact on the expression of both oncogenes, with transcriptional and translational downregulation occurring five days post-treatment. Out of the four tested PPRHs, MYC-targeting PPRHs, especially HpMYC-G4-PR-C directed against the promoter, showed a greater cytotoxic and expression modulation effect. When both KRAS- and MYC-targeting PPRHs were applied in combination, a synergistic reduction in cell viability was observed. Conclusion: The simultaneous targeting of KRAS and MYC demonstrates efficacy in gene modulation, thus in decreasing cell proliferation and viability.
引用
收藏
页数:17
相关论文
共 64 条
  • [31] Levens David, 2008, J Natl Cancer Inst Monogr, P41, DOI 10.1093/jncimonographs/lgn004
  • [32] The Relevance of G-Quadruplexes for DNA Repair
    Linke, Rebecca
    Limmer, Michaela
    Juranek, Stefan A.
    Heine, Annkristin
    Paeschke, Katrin
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (22)
  • [33] Therapeutic targeting of "undruggable" MYC
    Llombart, Victor
    Mansour, Marc R.
    [J]. EBIOMEDICINE, 2022, 75
  • [34] In Vitro and In Vivo Effects of the Combination of Polypurine Reverse Hoogsteen Hairpins against HER-2 and Trastuzumab in Breast Cancer Cells
    Lopez-Aguilar, Ester
    Fernandez-Nogueira, Patricia
    Fuster, Gemma
    Carbo, Neus
    Ciudad, Carlos J.
    Noe, Veronique
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (08)
  • [35] KRAS as a Therapeutic Target
    McCormick, Frank
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (08) : 1797 - 1801
  • [36] MYC - TIMELINE Reflecting on 25 years with MYC
    Meyer, Natalie
    Penn, Linda Z.
    [J]. NATURE REVIEWS CANCER, 2008, 8 (12) : 976 - 990
  • [37] Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis
    Mossafa, H.
    Damotte, D.
    Jenabian, A.
    Delarue, R.
    Vincenneau, A.
    Amouroux, I.
    Jeandel, R.
    Khoury, E.
    Martelli, J. M.
    Samson, T.
    Tapia, S.
    Flandrin, G.
    Troussard, X.
    [J]. LEUKEMIA & LYMPHOMA, 2006, 47 (09) : 1885 - 1893
  • [38] FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC
    Nakajima, Erica C.
    Drezner, Nicole
    Li, Xiaoxue
    Mishra-Kalyani, Pallavi S.
    Liu, Yajun
    Zhao, Hong
    Bi, Youwei
    Liu, Jiang
    Rahman, Atiqur
    Wearne, Emily
    Ojofeitimi, Idara
    Hotaki, Lauren Tesh
    Spillman, Dianne
    Pazdur, Richard
    Beaver, Julia A.
    Singh, Harpreet
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1482 - 1486
  • [39] Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer
    Neumann, Jens
    Zeindl--Eberhart, Evelyn
    Kirchner, Thomas
    Jung, Andreas
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2009, 205 (12) : 858 - 862
  • [40] Nucleic acids therapeutics using PolyPurine Reverse Hoogsteen hairpins
    Noe, Veronique
    Aubets, Eva
    Felix, Alex J.
    Ciudad, Carlos J.
    [J]. BIOCHEMICAL PHARMACOLOGY, 2021, 189